Congratulations to Captain T Cell, which joined us in Berlin for our 10th anniversary conference, on closing a €20 million financing round to advance its proprietary TCR-T pipeline into clinical development. 
The investment will fund the first-in-human Phase I trial of CTC127, a therapy using the patient's own cells to target MAGE-A4-positive solid tumors, and help develop a ready-to-use treatment option. Both programs aim to improve T cell persistence and resilience in challenging tumor microenvironments.

Captain T Cell at Frontiers Health 2025

They joined the global health innovation community at Frontiers Health 2025 in Berlin, contributing to two of the conference’s signature tracks. 

In the Beyond the Obvious: Molecular Medicine as it is Now session, Janna Hachmann, COO and co-founder, participated in discussions on emerging approaches to cancer treatment through advanced cell therapies.
It also featured its CEO and CSO, Felix Lorenz, in the Start-up and Scale-up Discovery Session, presenting its vision and clinical roadmap to investors and industry leaders.
Captain T Cell’s presence underscores its commitment to shaping the future of cancer treatment through advanced TCR-T platforms.

Date : November 17th, 2025 | Source: www.captaintcell.com